MEGAN CAMACHO: Open Payments
NPI 1467163733 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,311 in 56 payments from 17 companies in 2025. Trend: 2023 $335 · 2024 $1,351 · 2025 $1,311
Food & beverage: $1,311
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 9 | $209 |
| Otsuka America Pharmaceutical, Inc. | 7 | $176 |
| AstraZeneca Pharmaceuticals LP | 6 | $140 |
| Novartis Pharmaceuticals Corporation | 5 | $105 |
| Travere Therapeutics, Inc. | 5 | $93 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $88 |
| GlaxoSmithKline, LLC. | 3 | $75 |
| Ardelyx, Inc. | 2 | $56 |
| KYOWA KIRIN, INC. | 2 | $54 |
| Amgen Inc. | 3 | $52 |
Products named: TARPEYO, JYNARQUE, FARXIGA, Fabhalta, JARDIANCE, IBSRELA, CRYSVITA, SHINGRIX.
Industry payments across TX — which companies pay providers there.
